| Nov 12 |
Olema Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 6 |
Olema Oncology to Participate in Upcoming Investor Conferences
|
| Oct 31 |
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation
|
| Oct 23 |
Olema Oncology Presents Compelling New Preclinical Data Demonstrating Anti-Tumor Activity for OP-3136 with Enhanced Activity of Palazestrant Combinations at ENA 2024
|
| Oct 9 |
Olema Oncology Announces New Preclinical Combination Data to be Presented at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
|
| Sep 4 |
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
| Aug 21 |
Olema Oncology to Participate in Morgan Stanley 22nd Annual Global Healthcare Conference
|
| Aug 6 |
Olema Pharmaceuticals GAAP EPS of -$0.54 beats by $0.01
|
| Aug 6 |
Olema Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
|
| Aug 1 |
Recent Price Trend in Olema Pharmaceuticals (OLMA) is Your Friend, Here's Why
|
